,84,85,86 An FDA-approved long-acting Glp-1 analog, liraglutide, was shown in a phase 2 study (NCT01237119) to improve liver function and resolve pathological manifestations in NASH individuals with or without T2D.87 The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.